ACTC

San Diego Alzheimer's Partners Come Together

Retrieved on: 
Monday, March 18, 2024
Research, Partner, Aisén, Brain, MRI, Disease, CSF, SHARP, Diabetes, SAN, PET, Cerebrospinal fluid, Molina Healthcare, ACTC, Blood, Collection, Dementia, Amyloid, CBS 8

SAN DIEGO, March 18, 2024 /PRNewswire/ -- The Alzheimer's Therapeutic Research Institute (ATRI) and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024. A Day of SCervice, in support of accelerating Alzheimer's disease (AD) research through blood testing. Though the entire San Diego community is invited to visit ATRI and learn about new advances in AD research, those attending who are over the age of 55 and interested in participating in AD clinical trials can consent and, if eligible, have their blood drawn that day.

Key Points: 
  • SAN DIEGO, March 18, 2024 /PRNewswire/ -- The Alzheimer's Therapeutic Research Institute (ATRI) and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024.
  • Local CBS 8 news anchor and Alzheimer's San Diego Board Chair, Carlo Cecchetto, will moderate the morning panel.
  • "March 23 is also Day of SCervice, and the San Diego Trojan Family will be making a difference," said Shelley Moore, President-Elect of the San Diego Trojan League of San Diego County.
  • These clinical trials are vital to the work we do," said Janet Hamada-Kelley, Executive Director of the Alzheimer's Association San Diego & Imperial County an one of the event partners.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Biology, Work, Geographic atrophy, SHIMMER, Alzheimer's disease, Dementia, Neuron, ACTC, Iris (anatomy), EEG, Lewy body, RPE, Antibody, Letter, AMD, Brain, Therapy, Clinical trial, ADAS, SPARC, Society, DLB, SHINE, Cognition, Vance DeGeneres, Biomarker, Toxicity, Optimism, Manuscript, Cell, Patient, Magnification, Synapse, Diagnosis, Safety, Pharmaceutical industry

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

Retrieved on: 
Friday, October 27, 2023
NIA, Alzheimer's disease, Neuron, Physician, SHINE, START, Autophagy, ACTC, HIV disease progression rates, Clinical trial, SNAP, Disease, University, SPARC, National Institute on Aging, Therapy, Patient, SEQUEL, Bangladesh Technical Education Board, Pharmaceutical industry, Vaccine, Ageing, Cognition

The START Study is assessing once-daily oral CT1812 or placebo in 540 individuals with early Alzheimer’s disease for 18 months of treatment.

Key Points: 
  • The START Study is assessing once-daily oral CT1812 or placebo in 540 individuals with early Alzheimer’s disease for 18 months of treatment.
  • Cognition Therapeutics is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) with major grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
  • “The future treatment of Alzheimer’s disease will likely consist of combination therapies to achieve greater slowing of disease progression.
  • Ultimately, we expect that approximately 50 sites in North America, including premier institutions in the ACTC network, will be activated.

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

Retrieved on: 
Monday, October 16, 2023
Electroencephalography, SEQUEL, ACTC, Oscillation, Brain, Communication, Clinical trial, START, Cognition, Disease, EEG, FDA, Therapy, Doctor of Philosophy, Deficit spending, National Institute on Aging, AECC, Phase II, Medical imaging, Vaccine, Pharmaceutical industry, MD

PURCHASE, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced upcoming presentations from studies of CT1812, the Company's lead candidate for the treatment of adults with early, mild and moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference being held October 24-27, 2023 virtually and in person in Boston, MA.

Key Points: 
  • Cognition scientists and collaborators will present the complete electroencephalography (EEG) findings and proteomic analyses from the SEQUEL study .
  • Prior topline results showed that CT1812 had a beneficial impact on synapse function as measured by a positive change in brain waves patterns observed using quantitative EEG.
  • Specifically, participants treated with CT1812 exhibited fewer slow “theta” waves, which are associated with cognitive impairment, and proportionally more “alpha” waves compared to placebo-treated participants.
  • CT1812 also improved connectivity, as assessed by alpha AECc, which may indicate improved communication between different parts of the brain.

Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease

Retrieved on: 
Wednesday, July 5, 2023
Neuron, National Institute on Aging, University, START, NIA, DLB, Liver injury, Research, Bangladesh Technical Education Board, ACTC, Dementia, Synapse, Lewy body, Therapy, Neurology, MMSE, Pharmaceutical industry, Alzheimer's disease, Cognition, Ageing

NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that the first clinical trial site has been activated and can begin recruiting participants for the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease.

Key Points: 
  • NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that the first clinical trial site has been activated and can begin recruiting participants for the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease.
  • The University of Kentucky Sanders-Brown Center on Aging (SBCoA) is the first of approximately 50 sites in North America that has been activated by the Alzheimer's Clinical Trials Consortium (ACTC).
  • “Our START study represents a unique and important opportunity for Cognition to study CT1812 in people with early Alzheimer's disease,” added Cognition president and CEO, Lisa Ricciardi .
  • While trials in this patient population are crucial, the long treatment period required to show a change in cognition can be overly burdensome for small biotechnology companies.

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

Retrieved on: 
Wednesday, February 22, 2023
Therapy, University, Dementia, ACTC, Neuron, Research, Patient, Neurology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, National Institute on Aging, NIH, START, NIA, Bangladesh Technical Education Board, Neil Sedaka: The '50s and '60s, Food, Synapse, Pharmaceutical industry, Alzheimer's disease, Cognition

This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC).

Key Points: 
  • This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC).
  • , director of the Yale Alzheimer's Disease Research Center and primary investigator of the START study.
  • Our lead drug candidate is a potentially disease-modifying oral therapeutic for the treatment of Alzheimer's disease and other neurodegenerative conditions,” added Cognition president and CEO, Lisa Ricciardi .
  • Having an authorized protocol for the START study is a critical step in preparing to open clinical sites for the trial by mid-2023.”

AHEAD STUDY IS FIRST TO TEST LECANEMAB TO DELAY OR PREVENT ALZHEIMER'S DISEASE SYMPTOMS AT THE STAGE OF PRECLINICAL AD

Retrieved on: 
Wednesday, November 2, 2022
Amyloid, Plasma, Population, Headquarters, Clinical trial, Brain, Biomarker, Ageing, Research, PET, NIH, Harvard University, Risk, National Institute, Disease, Harvard Medical School, Safety, Neuroimaging, National, AD, Clarity, Biogen, BAN2401, Eisai, Dementia, NIA, Neurology, MCI, USC, ACTC, Multimedia, Clinical professor, SAN, Mayo Clinic, National Institute on Aging, Amnesia, Positron emission tomography, Medical imaging, Pharmaceutical industry, Online shopping, Alzheimer's disease

The AHEAD Study is the first ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer's disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as "preclinical" AD.

Key Points: 
  • The AHEAD Study is the first ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer's disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as "preclinical" AD.
  • The AHEAD Study is also the first AD trial to recruit people as young as 55 years old who are at risk of developing symptoms of AD as they get older.
  • The AHEAD Study will test whether the clinical effects reported in the Clarity AD clinically symptomatic population are similar in the AHEAD preclinical AD population.
  • "The AHEAD Study is testing lecanemab in a much earlier stage of AD than the Clarity AD trial," said Dr. Reisa Sperling, professor of neurology at Harvard Medical School, and co-principal investigator of the AHEAD Study.

MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

Retrieved on: 
Tuesday, August 9, 2022
CEO, Dementia, Good, TSX, Annual report, Research, Clinical trial, Keck School of Medicine of USC, Patient, Cannabis, Synthetic cannabinoids, Libby, Sponsor, National Institute on Aging, MD, OTCQX, FSE, Diagnosis, Enhanced Defense Cooperation Agreement, Agitation, Partnership, API, Hospital, Meta-analysis, National Institute, THC, Caregiver, The Journal of Clinical Psychiatry, Compliance, CNS Drugs (journal), Medication, Harvard Medical School, Ageing, ACTC, Alzheimer's Association, Mayo Clinic, Cone Health Women's Hospital, USC, Aggression, Principal investigator, Hospice, Quality of life, Company, CBD, Treatment, National, MBA, ISO, University, Adoption, Pharmaceutical industry, Medicinal plants, Medicine, Brigham, Alzheimer's disease

David Pidduck, CEO, MediPharm Labs commented, "We are proud to participate in this important research that further solidifies our pharmaceutical approach to medical cannabis.

Key Points: 
  • David Pidduck, CEO, MediPharm Labs commented, "We are proud to participate in this important research that further solidifies our pharmaceutical approach to medical cannabis.
  • This trial benefits from passionate lead investigators, a world-renowned sponsor institution and funding from the US National Institute of Health.
  • In this project, Keck School of Medicine has chosen to use a combination of two medications, THC and CBD.
  • Alzheimer's Clinical Trials Consortium(ACTC) is funded by a Cooperative Agreement from the National Institute on Aging, National Institutes of Health.